Early detection of type 1 diabetes via Exosome Technology with Optoelectronics Lab-on-chip: EXTOL

通过外泌体技术和光电子芯片实验室早期检测 1 型糖尿病：EXTOL

• 批准号: 10518728
• 负责人: Jason Gaglia
• 金额: $ 78.45万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10518728
• 关键词: Acoustics; Address; Affect; American; Autoimmune; Autoimmune Diseases; Benchmarking; Beta Cell; Biological Assay; Biological Markers; Biology; Cells; Clinical; Clinical Trials; Complement; DNA; Detection; Development; Devices; Diabetes Mellitus; Diagnosis; Disease; Early Diagnosis; Engineering; Environment; Expert Systems; Functional disorder; Genetic Markers; Hour; Inflammation; Insulin-Dependent Diabetes Mellitus; Interdisciplinary Study; Intervention; Islets of Langerhans; Label; MALDI-TOF Mass Spectrometry; Machine Learning; Membrane; Membrane Proteins; Metabolic Marker; Methods; MicroRNAs; Microfluidics; Monitor; Nature; Nucleic Acids; Optics; Outcome; Pancreatectomy; Patients; Persons; Phase; Plasma; Proteins; RNA; Research Personnel; Sampling; Standardization; Structure of beta Cell of islet; System; Systems Analysis; Technology; Time; United States; Work; base; biomarker discovery; detection platform; early detection biomarkers; exosome; experimental study; extracellular vesicles; high throughput screening; improved; innovation; islet; islet cell antibody; microRNA biomarkers; photonics; pre-clinical; protein biomarkers; response biomarker; sensor; treatment response

PROJECT SUMMARY Type 1 Diabetes (T1D) is an autoimmune disease affecting over 1.6 million people in the United States, and more than 5 million Americans are expected to be diagnosed with T1D by 2050. Clinical T1D is preceded by an occult period of autoimmune beta cell loss and dysfunction. Disease prediction can be performed for clinical trial purposes, with a combination of islet autoantibodies, genetic markers, and metabolic markers. However, the predictive ability in the short term, particularly early in the disease or as an early marker of response to therapy, is often inadequate. This results in needing longer and more extensive clinical trials for T1D interventions. Islet- derived exosomes (or small extracellular vesicles produced by pancreatic beta cells or nearby cells within the peri-islet environment) may reveal beta cell dysfunction and islet inflammation and are believed as promising biomarkers for early detection and monitoring of T1D, but little has been explored yet. Thus, there is an urgent and unmet need to identify and characterize islet-derived exosomes for the early detection of T1D, particularly during the asymptomatic phase. Our overall objective is to create an integrated exosome isolation and analysis system for the high throughput screening and identification of islet-derived exosomal markers with the rapid purification and specific detection of islet-derived exosomes in T1D. The rationale for the proposed work is to screen for pancreatic islet-specific exosomal markers and further develop an Exosome Technology with Optoelectronics Lab-on-chip (EXTOL) system for rapid and specific capturing and analyzing islet-derived exosomes in T1D. Then, we will validate the EXTOL system and screened exosomal markers using clinical samples from T1D patients and appropriate controls. The ultimate product of this study is to provide a new platform to screen, identify, and analyze exosomal markers for rapid and specific detection of asymptomatic T1D.

项目总结